U.S. – China Trade Agreement: China Agrees to Make Changes That Could Benefit U.S. Drug Companies Doing Business in China

Jan 21, 2020

Reading Time : 2 min

Most notably, China agreed to take steps to implement a patent resolution procedure, similar to that provided in the Hatch-Waxman Act, to resolve patent disputes before generic drugs enter the Chinese market. The Agreement leaves it to China to develop and implement the precise details for this patent resolution procedure consistent with its legal system. However, the Agreement requires that the procedure include a notification system whereby patent holders, licensees or parties who previously submitted safety and efficacy information to secure marketing approval are informed when another party seeks approval based on the same information. The procedure must also provide for a system to adjudicate patent rights and expeditious remedies, which will possibly include preliminary injunctive relief or equivalent measures.

China also agreed to allow pharmaceutical patent applicants to rely on supplemental data (for example, test results) to satisfy the requirements for patentability during patent examination, patent review and judicial proceedings. Implementing this provision will provide applicants and patent owners in China similar opportunities to present helpful supporting data as applicants and patent owners in the United States have enjoyed.

Finally, the Agreement provides that China will establish mechanisms to modify a patent’s term similar to those provided in 35 U.S.C. §§ 154, 156. Specifically, the Agreement allows term extensions for patents whose issuance is unreasonably delayed during examination for reasons not attributable to the applicant. The Agreement also provides that the terms of patents covering new pharmaceutical products (or methods of making or using such products) can be extended to compensate for unreasonable delays in receiving Chinese marketing approval. However, China may limit such adjustments to no more than five years, and may limit the resulting effective patent term to no more than 14 years from the date of marketing approval in China.

The Agreement provides China with 30 working days to promulgate an Action Plan identifying the measures it will take to implement its obligations related to intellectual property reform and the date by which the measures will go into effect. However, the ultimate impact of the Agreement will depend largely on when and how these provisions are implemented and on the strength of the protections ultimately provided. But at least on their face, the provisions of Chapter 1 of the Agreement represent a commitment from China to take steps to improve protections for innovative pharmaceutical companies.

Share This Insight

Previous Entries

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board determined that a reference could be used as prior art because patent owner failed to provide sufficient evidence that the prior art’s disclosure was invented by all four named inventors, and thus the same “inventive entity,” as the challenged claims.

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board rejected a patent owner’s assertion that petitioner should have named a third party, which was a defendant in a related district court patent infringement litigation and a party to a joint defense agreement (JDA) with petitioner, as a real party-in-interest (RPI). Had the board ruled otherwise and found the third party to be an RPI, the petition would have been time-barred under 35 U.S.C. § 315(b).

...

Read More

IP Newsflash

November 27, 2024

A district court recently refused to exclude testimony regarding consumer surveys conducted by a design patent expert, holding instead that the consumer surveys may be probative of how an ordinary observer would view the designs at issue, and thus could assist the factfinder in determining design patent infringement under the ordinary observer test.

...

Read More

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 10, 2024

In a patent case containing a variety of federal and state law claims, the District of Massachusetts retained supplemental jurisdiction over the state law claims even after all the federal law claims were dismissed.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.